IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT04626635 (COMBINE-EGFR-1) pour Tumeurs solides avancées est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche
Regeneron PharmaceuticalsA Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (COMBINE-EGFR-1) Phase I, Phase II 933
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT04626635 (COMBINE-EGFR-1) est conçu pour étudier le traitement de Tumeurs solides avancées. Il s'agit d'une étude interventionnel en Phase I Phase II. Son statut actuel est : en recrutement. L'étude a débuté le 21 décembre 2020 et vise à recruter 933 participants. Dirigée par Regeneron Pharmaceuticals, l'étude devrait être terminée d'ici le 7 avril 2027. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 2 février 2026.
Résumé succinct
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage.
The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the be...
Afficher plusTitre officiel
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Pathologies
Tumeurs solides avancéesAutres identifiants de l'étude
- COMBINE-EGFR-1
- R7075-ONC-2009
- 2022-501234-37-00 (Numéro CTIS (UE))
Numéro NCT
Date de début (réel)
2020-12-21
Dernière mise à jour publiée
2026-02-02
Date de fin (estimée)
2027-04-07
Inscription (estimée)
933
Type d'étude
Interventionnel
PHASE
Phase I
Phase II
Phase II
Statut
En recrutement
Mots clés
Variety of mixed advanced solid tumor types
First in Human (FIH)
First in Human (FIH)
Objectif principal
Traitement
Méthode d'allocation
Non randomisé
Modèle d'intervention
Séquentiel
Masquage
Aucun (ouvert)
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalDose Escalation Variety of mixed advanced solid tumor types | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion A Triple Negative Breast Cancer (TNBC) | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion B Cutaneous Squamous Cell Carcinoma (CSCC) | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion C Non-Small Cell Lung Cancer (NSCLC) | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection Platinum-based doublet chemotherapy Administered IV Q3W |
ExpérimentalDose Expansion D Head and Neck Squamous Cell Carcinoma (HNSCC) | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion E Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion F MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases) | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion G Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI) | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection Platinum-based doublet chemotherapy Administered IV Q3W |
ExpérimentalDose Expansion H EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection |
ExpérimentalDose Expansion I Third-line (3L) MSS-CRC with Active Liver Metastases | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection Bevacizumab Administered per protocol Trifluridine-tipiracil Administered per protocol |
ExpérimentalDose Expansion J 3L MSS-CRC without Active Liver Metastases | REGN7075 Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W) Cemiplimab Administered concomitantly Q3W by IV infusion or SC injection Bevacizumab Administered per protocol Trifluridine-tipiracil Administered per protocol |
Critère principal d'évaluation
Critère secondaire d'évaluation
| Critères d'évaluation | Description de la mesure | Période |
|---|---|---|
The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period | Dose escalation | Up to 6 weeks |
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) | Dose escalation | Approximately 90 days from last dose; up to 5 years |
Incidence and severity of Adverse Events of Special Interest (AESIs) | Dose escalation | Approximately 90 days from last dose; up to 5 years |
Incidence and severity of Serious Adverse Events (SAEs) | Dose escalation | Approximately 90 days from last dose; up to 5 years |
Incidence and severity of grade ≥3 laboratory abnormalities | Dose escalation | Approximately 90 days from last dose; up to 5 years |
Objective Response Rate (ORR) | Dose expansion | Up to 5 years |
| Critères d'évaluation | Description de la mesure | Période |
|---|---|---|
Concentrations of marlotamig in serum | Dose escalation and dose expansion | Up to 5 years |
ORR | Dose escalation | Up to 5 years |
Progression Free Survival (PFS) | Dose escalation and dose expansion | Up to 5 years |
Duration of Response (DOR) | Dose escalation and dose expansion | Up to 5 years |
Disease Control Rate (DCR) | Dose escalation and dose expansion | Up to 5 years |
Complete Response (CR) rate | Dose escalation and dose expansion | Up to 5 years |
Overall survival (OS) | Dose escalation and dose expansion | Up to 5 years |
Incidence of Anti-Drug Antibodies (ADA) to marlotamig | Dose escalation and dose expansion | Approximately 90 days from last dose; up to 5 years |
Magnitude of ADA to marlotamig | Dose escalation and dose expansion | Approximately 90 days from last dose; up to 5 years |
Incidence of ADA to cemiplimab | Dose escalation and dose expansion | Approximately 90 days from last dose; up to 5 years |
Magnitude of ADA to cemiplimab | Dose escalation and dose expansion | Approximately 90 days from last dose; up to 5 years |
The incidence and severity of TEAEs | Dose expansion | Approximately 90 days from last dose; up to 5 years |
The incidence and severity of AESIs | Dose expansion | Approximately 90 days from last dose; up to 5 years |
The incidence and severity of SAEs | Dose expansion | Approximately 90 days from last dose; up to 5 years |
The incidence and severity of grade ≥3 laboratory abnormalities | Dose expansion | Approximately 90 days from last dose; up to 5 years |
Patient reported Quality of Life (QoL) per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 | EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change. | Approximately 90 days from last dose; up to 5 years |
Patient reported Quality of Life (QoL) per EORTC QLQ-CR29 in CRC patients | The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales. | Approximately 90 days from last dose; up to 5 years |
Patient reported Quality of Life (QoL) per EORTC QLQ-BR23 in breast cancer patients | The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems. | Approximately 90 days from last dose; up to 5 years |
Patient reported Quality of Life (QoL) per EORTC QLQ-LC13 in NSCLC patients | The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much". | Approximately 90 days from last dose; up to 5 years |
Patient reported Quality of Life (QoL) per EORTC QLQ-HN35 in HNSCC patients | The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4. | Approximately 90 days from last dose; up to 5 years |
Patient reported Quality of Life (QoL) per EQ-5D-5L | The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. | Approximately 90 days from last dose; up to 5 years |
Patient reported symptoms per EORTC QLQ-C30 | EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change. | Approximately 90 days from last dose; up to 5 years |
Patient reported symptoms per EORTC QLQ-CR29 in CRC patients | The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). . Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales. | Approximately 90 days from last dose; up to 5 years |
Patient reported symptoms per EORTC QLQ-BR23 in breast cancer patients | The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems. | Approximately 90 days from last dose; up to 5 years |
Patient reported symptoms per EORTC QLQ-LC13 in NSCLC patients | The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much". | Approximately 90 days from last dose; up to 5 years |
Patient reported symptoms per EORTC QLQ-HN35 in HNSCC patients | The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4. | Approximately 90 days from last dose; up to 5 years |
Patient reported symptoms per EQ-5D-5L | The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. | Approximately 90 days from last dose; up to 5 years |
Patient reported functioning per EORTC QLQ-C30 | EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change. | Approximately 90 days from last dose; up to 5 years |
Patient reported functioning per EORTC QLQ-CR29 in CRC patients | The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales. | Approximately 90 days from last dose; up to 5 years |
Patient reported functioning per EORTC QLQ-BR23 in breast cancer patients | The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems. | Approximately 90 days from last dose; up to 5 years |
Patient reported functioning per EORTC QLQ-LC13 in NSCLC patients | The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much". | Approximately 90 days from last dose; up to 5 years |
Patient reported functioning per EORTC QLQ-HN35 in HNSCC patients | The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4. | Approximately 90 days from last dose; up to 5 years |
Patient reported functioning per EQ-5D-5L | The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. | Approximately 90 days from last dose; up to 5 years |
Patient reporting general health status per EORTC QLQ-C30 | EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change. | Approximately 90 days from last dose; up to 5 years |
Patient reporting general health status per EORTC QLQ-CR29 in CRC patients | The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales. | Approximately 90 days from last dose; up to 5 years |
Patient reporting general health status per EORTC QLQ-BR23 in breast cancer patients | The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems. | Approximately 90 days from last dose; up to 5 years |
Patient reporting general health status per EORTC QLQ-LC13 in NSCLC patients | The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much". | Approximately 90 days from last dose; up to 5 years |
Patient reporting general health status per EORTC QLQ-HN35 in HNSCC patients | The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4. | Approximately 90 days from last dose; up to 5 years |
Patient reporting general health status per EQ-5D-5L | The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. | Approximately 90 days from last dose; up to 5 years |
Assistant à la participation
Critères d'éligibilité
Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol
- Expansion Cohorts only: Is anti-Programmed cell Death protein-1 (PD-1)/Programmed cell Death Ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1
- Has at least 1 lesion that meets study criteria as defined in the protocol
- Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site that has not been previously irradiated
- Has adequate organ and bone marrow function as defined in the protocol
- In the judgement of the investigator, has a life expectancy of at least 3 months
- Is currently participating in another study of a therapeutic agent
- Has participated in any study of an investigational agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol
- Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities
- Has received recent anti-Epidermal Growth Factor Receptor (EGFR) antibody therapy as defined in the protocol
- Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events
- Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug.
- Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol
- Has second malignancy that is progressing or requires active treatment as defined in the protocol
- Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or any other condition that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, Central Nervous System (CNS) metastases, leptomeningeal disease, or spinal cord compression
- Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug
- Has any ongoing inflammatory skin disease as defined in the protocol
NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply
Regeneron Pharmaceuticals214 essais cliniques actifs à explorerContact central de l'étude
Contact: Clinical Trials Administrator, 844-734-6643, [email protected]
55 Centres de l'étude dans 7 pays
Auvergne-Rhone
Centre Leon Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL), Lyon, Auvergne-Rhone, 69008, France
En recrutement
Auvergne-Rhône
Centre Jean Perrin, Clermont-Ferrand, Auvergne-Rhône, 63011, France
Retiré
Hopital Lyon Sud, Pierre-Bénite, Auvergne-Rhône, 69310, France
En recrutement
Bourgogne-Franche-Comté
Centre Georges Francois Leclerc, Dijon, Bourgogne-Franche-Comté, 21034, France
En recrutement
Haute-Garonne
Institut Claudius Regaud, IUCT-Oncopole, Toulouse, Haute-Garonne, 31059, France
En recrutement
Nouvelle-Aquitaine
Institut Bergonie, Bordeaux, Nouvelle-Aquitaine, 33076, France
En recrutement
Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, Nouvelle-Aquitaine, 86021, France
En recrutement
Pays de la Loire Region
Nantes University Hospital, Nantes, Pays de la Loire Region, 44093, France
En recrutement
Provence Alpes Cote dAzur
Centre Antoine Lacassagne, Nice, Provence Alpes Cote dAzur, 06189, France
En recrutement
Hospital Paris Saint-Joseph, Paris, 75014, France
En recrutement
Île-de-France Region
Begin Army Instruction Hospital, Saint-Mandé, Île-de-France Region, 94240, France
En recrutement
Gustave Roussy, Villejuif, Île-de-France Region, 94800, France
En recrutement
California
Valkyrie Clinical Trials, Los Angeles, California, 90067, United States
En recrutement
University of California Los Angeles (UCLA) Medical Center, Los Angeles, California, 90095, United States
En recrutement
The Regents of the University of California, San Francisco, San Francisco, California, 94118, United States
En recrutement
Colorado
University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic, Aurora, Colorado, 80045, United States
En recrutement
Florida
University of Florida Health, Gainesville, Florida, 32608, United States
En recrutement
Moffitt Cancer Center, Tampa, Florida, 33612, United States
Terminé
Illinois
University of Illinois Cancer Center, Chicago, Illinois, 60612, United States
En recrutement
Iowa
University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States
En recrutement
Massachusetts
Dana Farber Cancer Institute Brookline Avenue, Boston, Massachusetts, 02215, United States
Retiré
Michigan
START Midwest - Cancer & Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, 49546, United States
En recrutement
New Jersey
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States
En recrutement
New York
Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States
En recrutement
Ohio
University of Cincinnati Medical Center, Cincinnati, Ohio, 45219, United States
En recrutement
The Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, 43212, United States
Terminé
Pennsylvania
Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States
En recrutement
Tennessee
Sarah Cannon Research Institute - 25th Ave, Nashville, Tennessee, 37203, United States
En recrutement
Texas
MD Anderson Cancer Center, Houston, Texas, 77030, United States
En recrutement
South Texas Oncology And Hematology, San Antonio, Texas, 78229, United States
Terminé
Washington
University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States
En recrutement
Wisconsin
Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
En recrutement
Central District
Sheba Medical Center, Ramat Gan, Central District, 5265601, Israel
En recrutement
Soroka University Medical Center, Beersheba, 84101, Israel
En recrutement
Rambam Health Care Campus, Haifa, 3109601, Israel
En recrutement
Shaare Zedek Medical Center, Jerusalem, 9103102, Israel
En recrutement
Hadassah Medical Center, Jerusalem, 91220, Israel
En recrutement
Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel
En recrutement
Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands
En recrutement
Erasmus MC, Rotterdam, 3015 GD, Netherlands
En recrutement
Wielkopolska
Medpolonia Sp. z o.o., Poznan, Wielkopolska, 60-693, Poland
En recrutement
Zach
Dom Lekarski SA, Szczecin, Zach, 70-784, Poland
En recrutement
Barcelona
Hospital General de Catalunya, Sant Cugat del Vallès, Barcelona, 08195, Spain
En recrutement
Madrid
Hospital Universitario Quiron Salud Madrid, Pozuelo de Alarcón, Madrid, 28223, Spain
En recrutement
Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain
En recrutement
Genesis Care Hospital San Francisco de Asis, Madrid, 28002, Spain
En recrutement
Hospital Clinico San Carlos, Madrid, 28040, Spain
En recrutement
Hospital Universitario Fundacion Jimenez Diaz, Madrid, 28040, Spain
En recrutement
Hospital 12 de Octubre, Madrid, 28041, Spain
En recrutement
Hospital Clinico Universitario - University of Valencia, Valencia, 28040, Spain
En recrutement
Adana
Baskent Universitesi, Yüreğir, Adana, 01120, Turkey (Türkiye)
En recrutement
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, 06200, Turkey (Türkiye)
En recrutement
Istanbul University Cerrahpasa at Cerrahpasa Medical Faculty, Istanbul, 34450, Turkey (Türkiye)
Retiré
Istanbul Medeniyet University - Prof Dr Suleyman Yalcin Sehir Hospital, Istanbul, 81450, Turkey (Türkiye)
En recrutement
Ciftlikkoy Campus Yenisehir Mersin, Mersin, 33343, Turkey (Türkiye)
En recrutement